Browse PDCD1LG2

Summary
SymbolPDCD1LG2
Nameprogrammed cell death 1 ligand 2
Aliases PD-L2; Btdc; PDL2; bA574F11.2; CD273; B7-DC; B7 dendritic cell molecule; B7DC; PDCD1L2; PD-1 ligand 2; PD-1- ......
Chromosomal Location9p24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 3: Secreted ; SUBCELLULAR LOCATION: Isoform 2: Endomembrane system Single-pass type I membrane protein ; SUBCELLULAR LOCATION: Isoform 1: Cell membrane Single-pass type I membrane protein
Domain PF08205 CD80-like C2-set immunoglobulin domain
Function

Involved in the costimulatory signal, essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production (By similarity).

> Gene Ontology
 
Biological Process GO:0001818 negative regulation of cytokine production
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0007159 leukocyte cell-cell adhesion
GO:0007162 negative regulation of cell adhesion
GO:0022407 regulation of cell-cell adhesion
GO:0022408 negative regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0031294 lymphocyte costimulation
GO:0031295 T cell costimulation
GO:0032609 interferon-gamma production
GO:0032613 interleukin-10 production
GO:0032649 regulation of interferon-gamma production
GO:0032653 regulation of interleukin-10 production
GO:0032689 negative regulation of interferon-gamma production
GO:0032693 negative regulation of interleukin-10 production
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032945 negative regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0042098 T cell proliferation
GO:0042102 positive regulation of T cell proliferation
GO:0042110 T cell activation
GO:0042129 regulation of T cell proliferation
GO:0042130 negative regulation of T cell proliferation
GO:0045785 positive regulation of cell adhesion
GO:0046006 regulation of activated T cell proliferation
GO:0046007 negative regulation of activated T cell proliferation
GO:0046651 lymphocyte proliferation
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050672 negative regulation of lymphocyte proliferation
GO:0050798 activated T cell proliferation
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050868 negative regulation of T cell activation
GO:0050870 positive regulation of T cell activation
GO:0051249 regulation of lymphocyte activation
GO:0051250 negative regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070664 negative regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0071593 lymphocyte aggregation
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903038 negative regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04514 Cell adhesion molecules (CAMs)
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-388841: Costimulation by the CD28 family
R-HSA-168256: Immune System
R-HSA-389948: PD-1 signaling
Summary
SymbolPDCD1LG2
Nameprogrammed cell death 1 ligand 2
Aliases PD-L2; Btdc; PDL2; bA574F11.2; CD273; B7-DC; B7 dendritic cell molecule; B7DC; PDCD1L2; PD-1 ligand 2; PD-1- ......
Chromosomal Location9p24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PDCD1LG2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PDCD1LG2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26081225Esophageal AdenocarcinomaInhibit immunity (T cell function)Because the progression from squamous esophagitis to Barrett's esophagus is accompanied by a transition from a TH1 to TH2 immune response, we hypothesized that the TH2 cytokines IL4/IL13 could contribute to PD-L2 induction. We confirmed that these cytokines can augment PD-L2 expression in esophageal adenocarcinoma cell lines.
29361059Renal Cell CarcinomaInhibit immunityPD-1, PD-L2, CTLA4 and FOXP3, all of which are implicated in the evasion of an anti-tumor immune response, had a significantly higher expression for samples representing co-detection of productive TcR-α and -β recombination reads.
28619999Head and Neck Squamous Cell CarcinomaInhibit immunity; Candidate for immunotherapy targetThe prevalence and distribution of PD-L2 correlated significantly with PD-L1 (P= 0.0012-<0.0001); however, PD-L2 was detected in the absence of PD-L1 in some tumor types. Response was greater in patients positive for both PD-L1 and PD-L2 (27.5%) than those positive only for PD-L1 (11.4%). PD-L2 status was also a significant predictor of progression-free survival (PFS) with pembrolizumab independent of PD-L1 status.
16864790MelanomaInhibit immunityIn this study, we created a PDL2-deficient mouse to characterize its function in T cell activation and tolerance. Antigen-presenting cells from PDL2-/- mice were found to be more potent in activation of T cells in vitro over the wild-type controls, which depended on PD-1. Upon immunization with chicken ovalbumin, PDL2-/- mice exhibited increased activation of CD4(+) and CD8(+) T cells in vivo when compared with WT animals. In addition, T cell tolerance to an oral antigen was abrogated by the lack of PDL2.
Summary
SymbolPDCD1LG2
Nameprogrammed cell death 1 ligand 2
Aliases PD-L2; Btdc; PDL2; bA574F11.2; CD273; B7-DC; B7 dendritic cell molecule; B7DC; PDCD1L2; PD-1 ligand 2; PD-1- ......
Chromosomal Location9p24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PDCD1LG2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPDCD1LG2
Nameprogrammed cell death 1 ligand 2
Aliases PD-L2; Btdc; PDL2; bA574F11.2; CD273; B7-DC; B7 dendritic cell molecule; B7DC; PDCD1L2; PD-1 ligand 2; PD-1- ......
Chromosomal Location9p24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PDCD1LG2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2580.523
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.10.913
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.370.591
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.6680.12
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6140.59
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7350.584
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2790.575
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.770.437
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3070.785
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.2620.116
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3270.295
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1320.524
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PDCD1LG2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPDCD1LG2
Nameprogrammed cell death 1 ligand 2
Aliases PD-L2; Btdc; PDL2; bA574F11.2; CD273; B7-DC; B7 dendritic cell molecule; B7DC; PDCD1L2; PD-1 ligand 2; PD-1- ......
Chromosomal Location9p24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PDCD1LG2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPDCD1LG2
Nameprogrammed cell death 1 ligand 2
Aliases PD-L2; Btdc; PDL2; bA574F11.2; CD273; B7-DC; B7 dendritic cell molecule; B7DC; PDCD1L2; PD-1 ligand 2; PD-1- ......
Chromosomal Location9p24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PDCD1LG2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PDCD1LG2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPDCD1LG2
Nameprogrammed cell death 1 ligand 2
Aliases PD-L2; Btdc; PDL2; bA574F11.2; CD273; B7-DC; B7 dendritic cell molecule; B7DC; PDCD1L2; PD-1 ligand 2; PD-1- ......
Chromosomal Location9p24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PDCD1LG2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPDCD1LG2
Nameprogrammed cell death 1 ligand 2
Aliases PD-L2; Btdc; PDL2; bA574F11.2; CD273; B7-DC; B7 dendritic cell molecule; B7DC; PDCD1L2; PD-1 ligand 2; PD-1- ......
Chromosomal Location9p24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PDCD1LG2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPDCD1LG2
Nameprogrammed cell death 1 ligand 2
Aliases PD-L2; Btdc; PDL2; bA574F11.2; CD273; B7-DC; B7 dendritic cell molecule; B7DC; PDCD1L2; PD-1 ligand 2; PD-1- ......
Chromosomal Location9p24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PDCD1LG2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPDCD1LG2
Nameprogrammed cell death 1 ligand 2
Aliases PD-L2; Btdc; PDL2; bA574F11.2; CD273; B7-DC; B7 dendritic cell molecule; B7DC; PDCD1L2; PD-1 ligand 2; PD-1- ......
Chromosomal Location9p24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PDCD1LG2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.